Email

weborders@prabadincorp.com

Call us

+1 (786)-332-3938
Drug Test
  • April 14, 2025

Synthesis and analytical characterization of 1‐(2‐thienoyl)‐6‐allyl‐nor‐d‐lysergic acid diethylamide (1T‐AL‐LAD)

Abstract Lysergic acid diethylamide (LSD) analogs have emerged as new psychoactive substances (NPS) since the mid-2010s, and new compounds continue…
Drug Test
  • April 14, 2025

In vitro activation of the CB1 receptor by the semi‐synthetic cannabinoids hexahydrocannabinol (HHC), hexahydrocannabinol acetate (HHC‐O) and hexahydrocannabiphorol (HHC‐P)

The semi-synthetic cannabinoids market is developing rapidly, and 24 European countries have identified HHC, often sold openly. This study characterized…
Drug Test
  • April 14, 2025

Cover Picture

fda-approves-nivolumab-with-ipilimumab-for-unresectable-or-metastatic-hepatocellular-carcinoma Drug Test
  • April 11, 2025

FDA approves nivolumab with ipilimumab for unresectable or metastatic hepatocellular carcinoma

On April 11, 2025, the Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers Squibb Company) with ipilimumab (Yervoy, Bristol…
sunscreen-meetings Drug Test
  • April 11, 2025

Sunscreen Meetings

Sunscreen Meetings
Drug Test
  • April 11, 2025

Optimization of Parallel Artificial Liquid Membrane Extraction for the Determination of Over 50 Psychoactive Substances in Oral Fluid Through UHPLC–MS/MS

This study is related to the development of a microextraction method for the determination of 56 psychoactive substances in oral…
fda-announces-plan-to-phase-out-animal-testing-requirement-for-monoclonal-antibodies-and-other-drugs Drug Test
  • April 10, 2025

FDA Announces Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs

FDA Announces Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs
other-|-cancer-accelerated-approvals Drug Test
  • April 10, 2025

Other | Cancer Accelerated Approvals

This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have been granted for supportive care products…
fda-listing-of-authorized-generics Drug Test
  • April 9, 2025

FDA Listing of Authorized Generics

FDA Listing of Authorized Generics
fda-approves-nivolumab-with-ipilimumab-for-unresectable-or-metastatic-msi-h-or-dmmr-colorectal-cancer Drug Test
  • April 8, 2025

FDA approves nivolumab with ipilimumab for unresectable or metastatic MSI-H or dMMR colorectal cancer

On April 8, 2025, the FDA approved nivolumab (Opdivo, Bristol Myers Squibb Company) with ipilimumab (Yervoy, Bristol Myers Squibb Company)…